<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">327</article-id><article-id pub-id-type="doi">10.36691/RJA327</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Experience of modern skin care series Atopic® using in atopic dermatitis children</article-title><trans-title-group xml:lang="ru"><trans-title>Опыт использования современных средств по уходу за кожей серии Атопик® у детей с атопическим дерматитом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Elisyutina</surname><given-names>O G</given-names></name><name xml:lang="ru"><surname>Елисютина</surname><given-names>Ольга Гурьевна</given-names></name></name-alternatives><email>el-olga@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Litovkina</surname><given-names>A O</given-names></name><name xml:lang="ru"><surname>Литовкина</surname><given-names>А О</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Fedenko</surname><given-names>E S</given-names></name><name xml:lang="ru"><surname>Феденко</surname><given-names>Е С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Immunology</institution></aff><aff><institution xml:lang="ru">ФГБУ «ГНЦ Институт иммунологии» ФМБА России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2017</year></pub-date><volume>14</volume><issue>2</issue><issue-title xml:lang="en">VOL 14, NO2 (2017)</issue-title><issue-title xml:lang="ru">ТОМ 14, №2 (2017)</issue-title><fpage>76</fpage><lpage>81</lpage><history><date date-type="received" iso-8601-date="2020-03-10"><day>10</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, Фармарус Принт Медиа</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2019-12-15"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/327">https://rusalljournal.ru/raj/article/view/327</self-uri><abstract xml:lang="en"><p>Atopic dermatitis - chronic allergic skin inflammatory disease with genetic predisposition, dysbalance of immune response, dysfunction of an epidermal barrier and influence of various exogenous and endogenous factors. Epidermal barrier dysfunction leads to rising of permeability of a skin for allergens, microbs and nonspecific stimuli, as well as to sensitivity to various external influences. Clinically these implications are shown by skin xerosis symptoms therefore. According to modern clinical guidelines, the moisturizing agents, so called emollients, have to be used at all disease stages. Own data on use of modern skin care series Atopic® in complex therapy of atopic dermatitis patients are presented in the article.</p></abstract><trans-abstract xml:lang="ru"><p>Атопический дерматит (АтД) - хроническое многофакторное воспалительное заболевание кожи, в развитии которого участвуют генетические нарушения, дисбаланс иммунного ответа, нарушение функций эпидермального барьера и влияние различных экзогенных и эндогенных факторов. Нарушения эпидермального барьера являются одним из ведущих механизмов развития АтД и приводят к повышению проницаемости кожи для аллергенов и неспецифических раздражителей, чувствительности к различным внешним воздействиям, а также изменениям барьерной функции кожи и увеличению риска присоединения вторичной инфекции. Клинически данные проявления проявляются симптомами ксероза кожи, поэтому в соответствии с современными клиническими рекомендациями увлажняющие средства должны использоваться на всех стадиях АтД. В статье представлены собственные данные о применении современных эмолентов линии Atopic® в комплексной терапии больных АтД.</p></trans-abstract><kwd-group xml:lang="en"><kwd>STIMU-TEX</kwd><kwd>atopic dermatitis</kwd><kwd>epidermal barrier</kwd><kwd>emollients</kwd><kwd>STIMU-TEX</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>атопический дерматит</kwd><kwd>эпидермальный барьер</kwd><kwd>эмоленты</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Хаитов Р.М., Ильина Н.И. Аллергология. Федеральные клинические рекомендации. М., «Фармарус Принт Медиа». 2014, 124 с.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Bouwstra J.A., Pilgrim K., Ponec M. Structure of the skin barrier, in Skin barrier, edited by P.M. Elias, K.R. Feingold. New York, Naylor and Francis. 2006, 65 p.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kezic S., Novak N., Jakasa I. et al. Skin barrier in atopic dermatitis. Front Biosci. 2014, v. 1, p. 542-556.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Гущин И.С. Эпидермальный барьер и аллергия. Рос. Аллергол. Журн. 2007, № 2, с. 3-16.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Irvine A.D., McLean W.H., Leung D.Y Filaggrin mutations associated with skin and allergic diseases. N. Engl. J. Med. 2011, v. 365, p. 1315-1327.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Baek J.H., Lee S.E., Choi K.J. et al. Acute modulations in stratum corneum permeability barrier function affect claudin expression and epidermal tight junction function via changes of epidermal calcium gradient. Yonsey Med. J. 2013, v. 54, p. 523-528.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Elias P.M., Eichenfield L.F., Fowler J.F. Jr. et al. Update on the structure and function of the skin barrier: atopic dermatitis as an exemplar of clinical implications. Semin. Cutan. Med. Surg. 2013, v. 32, p. 21-24.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Lee S.E., Jeong S.K., Lee S.H. Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis. Yonsei Med. J. 2010, v. 51, p. 808-822.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Adachi Y., Hatano Y., Sakai T., Fujiwara S. Expressions of peroxisome proliferator-activated receptors (PPARs) are directly influenced by permeability barrier abrogation and inflammatory cytokines and depressed PRAPalpha modulates expressions of chemokines and epidermal differentiation-related molecules in keratinocytes. Exp. Dermatol. 2013, v. 22, p. 606-608.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Afshar M., Gallo R.L. Innate immune defense system of the skin. Vet. Dermatol. 2013, v. 24, p. 32-38.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Janssens M., van Smeden J., Gooris G.S. et al. Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients J. Lipid. Res. 2012, v. 53, p. 2755-2766.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Di Nardo A., Wertz P., Giannetti A., Seidenari S. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm. Venereol. 1998, v. 78, p. 27-30.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Breternitz M., Kowatzki D., Langenauer M. et al. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin. Pharmacol. Physiol. 2008, v. 21, p. 39-45.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Ring J., Alomar A., Bieber T. et al. Guidelines for treatment of atopic eczema (atopic dermatitis). Part I. J. Eur. Acad. Dermatol. Venereol. 2012, v. 26, p. 1045-1060.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Eichenfield L.F., Tom W.L., Berger T.G. et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J. Am. Acad. Dermatol. 2014, v. 71, p. 116-132.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Simpson E. Improvement of skin barrier function in atopic dermatitis patients with a new moisturizer containing a ceramide precursor. J. Dermatol. Treat. 2013, v. 24, p. 122-125.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Korting H.C., Schollmann C., Cholcha W. et al. Efficacy and tolerability of pale sulfonated shale oil cream 4% in the treatment of mild to moderate atopic eczema in children: a multicentre, randomized vehicle-controlled trial. J. Eur. Acad. Dermatol. Venereol. 2010, v. 24, p. 1176-1182.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Grimalt R., Mengeaud V., Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007, v. 214, p. 61-67.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Msika P., De Belilovsky C., Piccardi N. et al. New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. Pediatr. Dermatol. 2008, v. 25, p. 606-612.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Kownacki S. The importance of emollients in treating the increasing incidence of atopic eczema. Nurs. Times. 2009, v. 105 (28), p. 18-22.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Тлиш М.М., Глузмин М.И., Карташевская М.И., Псавок Ф.А. Атопический дерматит у детей: перспективы применения инновационных средств в наружной терапии. Вестник дерматологии и венерологии. 2016, № 2, с. 96-102.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Stadler J.F., Taieb A. Severity scoring ofatopic dermatitis: the SCORAD index. Consensus report ofthe European task force on atopic dermatitis. Dermatology. 1993, v. 186, p. 23-31.</mixed-citation></ref></ref-list></back></article>
